LunAIRo
98 evidence topics · 19 sources
Objective
Primary and secondary objectives in the design paper
“The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional objectives for the LunAIRo trial include exploring both long-term efficacy and safety endpoints over a 51-week placebo-controlled period, and exploring time points as early as 4 weeks to evaluate rapid onset of efficacy of AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study rationale and purpose in the protocol
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2023-08-28” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-05-07” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-05-07” (opens the source at this quote in a new tab)
“Results First Posted 2026-11-03” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Sites in the United States
“A total of 64 sites have been identified in the U.S. for LunAIRo (Supplemental Table 1) and 73 sites have been identified in both the U.S. and Canada for SynAIRgy (Supplemental Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial initiation and completion in the prospectus
Study design
Design, randomization, and duration in the protocol
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)” |
| Other study ID | “APC-APN-304” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Enrollment | “Enrollment (Actual) 660” |
Stratified randomization and severity strata
“Randomization is stratified according to baseline AHI4 (<15, 15 to 30, >30) and 8-item PROMIS-Fatigue raw score (<25 vs ≥ 25; a raw score of 25 is equivalent to a T-score of 58.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Polysomnography schedule and central scoring
“Objective efficacy data are gathered with in-laboratory polysomnograms (PSG) performed at 13, 26, and 51 weeks for the LunAIRo study, and at 4 and 26 weeks for the SynAIRgy study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ambulatory blood pressure monitoring and blinding
“Eligible participants in the LunAIRo trial, after V2, will be encouraged to undergo optional 24 h ambulatory blood pressure monitoring (ABPM) before the randomization visit (V3). The ABPM procedure is repeated after 4 weeks of treatment with AD109 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension after the trial
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Apnea-hypopnea index range and PAP criteria in protocol version 4.0
Apnea-hypopnea index range in the baseline abstract
“Since the mechanism of action should apply, in theory, to all OSA patients, no limit to OSA severity is implemented initially, however caps could be implemented during the trial to ensure that the full range of OSA severities are well-represented in the trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria and fatigue threshold in the design paper
“Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA). Participants treated with insomnia can be enrolled if symptoms are controlled” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only participants who refuse or are intolerant to PAP and with a raw PROMIS-Fatigue score ≥17 (fatigue level above average of the population; a raw score of 17 is equivalent to a T-score of 50.4) are eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disallowed concomitant medications
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MAOIs, NRIs, and TCAs,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs used exclusively for weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Modafinil, armodafinil, solriamfetol, and pitolisant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral anticholinergics, and cholinesterase inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Treatment arms in the ClinicalTrials.gov record
No dose reduction, and continued follow-up after discontinuation
PAP initiation permitted during the trial
“Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: change from baseline in AHI4 at week 26
Protocol amendment 4.0: reordering of the primary and key secondary endpoints, June 2025
Primary endpoint: proportion with at least 50% reduction in AHI4 at six months in the baseline abstract, May 2025, superseded in June 2025
Key secondary and secondary endpoints, in the order tested
Apnea-hypopnea index as the historical principal biomarker, and hypoxic burden as a complementary metric
“The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16]. This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue as a key secondary endpoint
“Fatigue is one of the most common patient-reported symptoms in relationship to sleep apnea and disturbed sleep, together with sleepiness [18].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company interpretation of absolute and relative AHI reductions in a mostly mild-to-moderate population
FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results and the limits of the patient-reported outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed for the primary endpoint, by estimand
Description of analysis sets
Analysis sets in the statistical analysis plan
Analysis populations in the ClinicalTrials.gov record
Treatment policy estimand for the primary endpoint
While-on-treatment estimand as a supportive analysis
Statistical model for the primary endpoint
“The primary analysis methodology will utilize a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants with ≥50% reduction in AHI4 at Week 26 will be compared between treatment groups using the stratified Cochran-Mantel Haenszel procedure, controlling for randomization strata.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control for the key secondary endpoints
Week 51 endpoints analyzed as tertiary endpoints
Pooled phase 3 analysis: estimands and analysis sets
Results
Participant disposition
Treatment discontinuation due to adverse events and overall treatment discontinuation by month 6 and month 12
Pooled phase 3 analysis: study completion and overall treatment discontinuation by week 26
Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26
Baseline characteristics
Baseline characteristics in the design paper
Baseline characteristics of the full analysis set in the ClinicalTrials.gov record
| Characteristic | AD109 (n = 324) | Placebo (n = 326) |
|---|---|---|
| Age, years, mean (SD) | “57.2(10.26)” | “57.4(10.72)” |
| Female | “160” | “138” |
| Male | “164” | “188” |
| Black or African American | “58” | “53” |
| White | “238” | “246” |
| Baseline AHI4 below 15 | “119” | “125” |
| Baseline AHI4 15 to 30 | “109” | “104” |
| Baseline AHI4 above 30 | “96” | “97” |
| Baseline AHI4, events/hr, mean (SD) | “24.03(16.692)” | “24.69(18.735)” |
Demographics, AHI4 severity, and symptoms in the baseline abstract
Median baseline AHI4 in the on-treatment set
Pooled phase 3 analysis: baseline severity and AHI distribution
Efficacy results
Week 26 change from baseline in AHI4, treatment policy and while-on-treatment estimands, in the ClinicalTrials.gov record
| Comparison | LS mean difference | Lower 95% CI | Upper 95% CI | p-value |
|---|---|---|---|---|
| “Analyses were conducted under the Treatment Policy estimand” | “-4.08” | “-6.14” | “-2.03” | “<0.001” |
| “Analyses were conducted under the While-on-Treatment Estimand” | “-5.81” | “-8.07” | “-3.55” | “<0.0001” |
Week 26 change in AHI4, treatment policy estimand (ITT set)
Week 26 relative change in AHI4, treatment policy and on-treatment estimands
Week 26 and week 51 change in AHI4, on-treatment estimand (mITT set)
Week 26 and week 51 AHI reduction as reported in the company release
Attenuation of the treatment policy estimate at week 51
Key secondary endpoint: week 26 ODI3, on-treatment estimand (mITT set)
Key secondary endpoint: week 26 ODI3, treatment policy and on-treatment estimands
Key secondary endpoint: week 26 hypoxic burden, treatment policy and on-treatment estimands
Key secondary endpoint: at least 50% reduction in AHI4 at week 26, on-treatment estimand (mITT set)
Key secondary endpoint: at least 50% reduction in AHI at week 26, treatment policy and on-treatment estimands
Severity category improvement and disease control at week 26, on-treatment estimand (mITT set)
Severity category improvement and disease control at weeks 26 and 51, as reported in the company release
Apnea index and hypopnea index at week 26, estimand not stated
Pooled phase 3 analysis: week 26 change in AHI4, treatment policy estimand
Pooled phase 3 analysis: week 26 change in AHI4, on-treatment estimand
Pooled phase 3 analysis: responders, disease control, and hypoxic burden, treatment policy estimand
Pooled phase 3 analysis: responders, disease control, and hypoxic burden, reported after the on-treatment estimand results
Pooled phase 3 analysis: severity category improvement and disease control, treatment policy and on-treatment estimands
Pooled phase 3 analysis: week 26 AHI adjusted for changes in REM sleep and BMI, on-treatment estimand
| Model, LS mean (95% CI), events/h at week 26 | AD109 (n = 500) | Placebo (n = 589) | Estimated treatment difference (95% CI) | p-value |
|---|---|---|---|---|
| Primary model for change from baseline in AHI | “–6.1 (–7.3 to –4.9)” | “0.1 (–1.0 to 1.2)” | “–6.2 (–7.8 to –4.6)” | “<0.0001” |
| Model adjusted for change in proportion of REM sleep | “–5.7 (–7.1 to –4.2)” | “0.2 (–1.1 to 1.4)” | “–5.9 (–7.9 to –3.8)” | “<0.0001” |
| Model adjusted for change in BMI | “–5.1 (–6.4 to -3.8)” | “–0.2 (–1.4 to 0.9)” | “–4.9 (–6.6 to –3.1)” | “<0.0001” |
Pooled phase 3 analysis: snoring frequency at week 26 in participants with an on-treatment polysomnogram
Pooled phase 3 analysis: modeled cardiovascular risk reduction from hypoxic burden, treatment policy and on-treatment estimands
Pooled phase 3 analysis: AHI response with concomitant GLP-1 receptor agonists, estimand not stated
Pooled phase 3 analysis: body weight change with concomitant GLP-1 receptor agonists for diabetes, exploratory, estimand not stated
Health-related quality of life and patient-reported outcomes
Key secondary endpoint: week 26 PROMIS-Fatigue T-score, on-treatment estimand (mITT set)
Week 26 PROMIS-Fatigue and PROMIS-Sleep Impairment, treatment policy and on-treatment estimands
Pooled phase 3 analysis: week 26 PROMIS-Fatigue, PROMIS-Sleep Impairment, and ESS, on-treatment estimand
Pooled phase 3 analysis: participants with baseline ESS of 10 or more, on-treatment estimand
Pooled phase 3 analysis: participants with baseline ESS of 10 or more, treatment policy estimand
Pooled phase 3 analysis: per-protocol set, treatment policy estimand dataset
Pooled phase 3 analysis: association between baseline AHI and baseline patient-reported outcomes
Safety results
Overall adverse events and most common adverse events
Adverse event reporting period and definition
Non-serious adverse events in at least 5% of participants in either arm
| Adverse event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
|---|---|---|
| Total | “220/328 (67.07%)” | “122/327 (37.31%)” |
| Dry mouth | “130/328 (39.63%)” | “31/327 (9.48%)” |
| Middle insomnia | “44/328 (13.41%)” | “13/327 (3.98%)” |
| Nausea | “43/328 (13.11%)” | “7/327 (2.14%)” |
| Initial insomnia | “32/328 (9.76%)” | “12/327 (3.67%)” |
| Urinary hesitation | “27/328 (8.23%)” | “2/327 (0.61%)” |
| Somnolence | “24/328 (7.32%)” | “12/327 (3.67%)” |
| Headache | “22/328 (6.71%)” | “23/327 (7.03%)” |
| Dyspepsia | “20/328 (6.10%)” | “7/327 (2.14%)” |
| Urinary tract infection | “20/328 (6.10%)” | “10/327 (3.06%)” |
| Constipation | “19/328 (5.79%)” | “8/327 (2.45%)” |
| Upper respiratory tract infection | “19/328 (5.79%)” | “26/327 (7.95%)” |
| Dizziness | “17/328 (5.18%)” | “6/327 (1.83%)” |
| COVID-19 | “14/328 (4.27%)” | “25/327 (7.65%)” |
Serious adverse events and deaths
| Event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
|---|---|---|
| All-cause mortality | “0/328 (0.00%)” | “0/327 (0.00%)” |
| Any serious adverse event | “5/328 (1.52%)” | “10/327 (3.06%)” |
| Acute myocardial infarction | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Aortic dissection | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Intracranial aneurysm | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Ischaemic stroke | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Suicide attempt | “0/328 (0.00%)” | “1/327 (0.31%)” |
Relatedness of serious adverse events as classified in the ClinicalTrials.gov record
Absence of serious adverse events related to AD109
Pooled phase 3 analysis: overall and most common treatment-emergent adverse events
Pooled phase 3 analysis: major adverse cardiovascular events
Pooled phase 3 analysis: heart rate and blood pressure, safety analysis set
| Measure | AD109 (n = 653) | Placebo (n = 646) | p-value |
|---|---|---|---|
| Heart rate, beats/min, mean change (SD) to week 26, evening pre-PSG | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate, beats/min, mean change (SD) to week 26, morning post-PSG | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |
Phase 3 program: onset, duration, and severity of insomnia
Study limitations
Summary
- Publication status: results are available from a congress abstract, the registry results (first posted 2026-11-03), company releases, and the prospectus; the 2026 editorial on SynAIRgy described LunAIRo results as forthcoming.
- Design: placebo-controlled for 51 weeks, with the primary endpoint at week 26; week 51 efficacy was analyzed as a tertiary endpoint. No active comparator was used, dose reduction was not permitted, and all 64 sites were in the United States.
- Population: adults intolerant of or refusing PAP with a PROMIS-Fatigue raw score of at least 17, and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included bothersome insomnia, clinically significant cardiac disease, blood pressure above 145/90 mmHg, specified psychiatric disorders, and narrow angle glaucoma.
- Eligibility AHI differs by source: protocol version 4.0 states AHI4 of more than 5 and up to 45, the registry states AHI of more than 5, and the baseline abstract states no upper limit. The design paper states caps could be added during the trial.
- Severity mix: in the pooled phase 3 population, 51% had AHI below 20 events/h and 74% below 30, per the prospectus.
- Endpoint change: the 2025 baseline abstract named the proportion with at least 50% AHI4 reduction at six months as the primary endpoint. Protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry's actual primary completion date (2025-05-07).
- Estimands and missing data: the treatment policy estimand assumed data missing not at random with control-based imputation. The on-treatment estimand excluded data after treatment discontinuation with last observation carried forward and included 240 participants on AD109 and 293 on placebo, against 324 and 326 in the full analysis set. The company states the on-treatment estimand gave the most clinically relevant estimate, and attributes the smaller week 51 response to higher discontinuation with AD109 and control-based imputation. The topline release reported the on-treatment relative reduction (46.8%).
- Analysis-set exclusions: participants at site 1308 were excluded from the full analysis set after the site was terminated.
- Discontinuation: treatment discontinuation due to adverse events was 23.7% with AD109 and 6.6% with placebo by month 6 and 28.6% and 10.0% by month 12; overall treatment discontinuation at month 12 was 46.5% and 25.1% (prospectus, main cohort). In the registry, 250 of 329 participants on AD109 and 274 of 331 on placebo completed the study.
- Patient-reported outcomes: AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand, and no treatment effect was observed on PROMIS Sleep Impairment.
- Pooled analyses: Patel et al. (2026a) reports the pooled 39.0% versus 18.8% responder result without an estimand label, while the prospectus labels the pooled 39% as on treatment. The prospectus states the phase 3 trials were not designed or powered to assess cardiovascular outcomes.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed.
- Sponsor: the prospectus describes LunAIRo as a trial the company initiated.